Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Atrial Fibrillation
Interventions
DRUG

Interrupted apixaban

Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.

DRUG

Uninterrupted apixaban

Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.

Trial Locations (19)

19019

Site 0009, Philadelphia

23219

Site 0003, Richmond

29401

Site 0010, Charleston

32501

Site 0016, Pensacola

35801

Site 0020, Huntsville

43615

Site 0002, Toledo

50266

Site 0014, West Des Moines

64111

Site 0006, Kansas City

68131

Site 0021, Omaha

73104

Site 0007, Oklahoma City

78705

Site 0017, Austin

87101

Site 0019, Albuquerque

92690

Site 0005, Mission Viejo

06501

Site 0012, New Haven

06611

Site 0011, Trumbull

04401

Site 0018, Bangor

04074

Site 0004, Scarborough

02118

Site 0008, Boston

01805

Site 0001, Burlington

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Baim Institute for Clinical Research

OTHER